Sanofi LA updates
Join to myFT Daily Digest to be the first to know about Sanofi SOCIAL FEAR news.
Sanofi said it would halt progress its vaccine against Covid-19 based on mRNA technology no matter it having showed beneficial early-stage trial results.
The French pharma organisation} is also working on another coronavirus jab, in partnership with GlaxoSmithKline, anchored in a more traditional manufacturing technique, which will it aims to bring to existing by the end of the year if or when regulators approve.
“There is no public health need for an another messenger RNA vaccine” against Covid-19, Thomas Triomphe, the company’s head of vaccines, spoke to AFP.
The move shows how your advent of the new technology sometimes known as mRNA has upended this particular once staid vaccine business model, leaving once leading service provider such as Sanofi and Merck racing to catch up. Innovative new players such as Moderna and as a consequence BioNTech, which teamed up along with Pfizer, have taken most of the multibillion-dollar market for Covid-19 vaccines.
Sanofi said it was not breaking mRNA completely and does continue to work on jabs to suit other diseases such as winter flu, but that it was simply too lurking behind to market for the mRNA Covid-19 to be useful.
It said it might aim to get its “modified quadrivalent flu mRNA vaccine in the clinic in 2022”. It is in early-stages rated trials now.
But Sanofi generally falling behind again since its US rival Pfizer rumoured on Monday that it was getting started human trials for its mRNA flu vaccine now.
Sanofi acquired almost €6bn in revenue from vaccines last year, most notably €2. 5bn from flu virus vaccines.
Sanofi to stop development of Covid vaccine based on mRNA technology
Pinoy Variant